- Home
- DSGN vs WNEB Comparison
DSGN vs WNEB Comparison
Compare DSGN & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- WNEB
- Stock Information
- Founded
- DSGN 2017
- WNEB 1853
- Country
- DSGN United States
- WNEB United States
- Employees
- DSGN N/A
- WNEB N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- WNEB Savings Institutions
- Sector
- DSGN Health Care
- WNEB Finance
- Exchange
- DSGN Nasdaq
- WNEB Nasdaq
- Market Cap
- DSGN 208.9M
- WNEB 195.7M
- IPO Year
- DSGN 2021
- WNEB N/A
- Fundamental
- Price
- DSGN $5.26
- WNEB $12.37
- Analyst Decision
- DSGN
- WNEB Buy
- Analyst Count
- DSGN 0
- WNEB 2
- Target Price
- DSGN N/A
- WNEB $11.00
- AVG Volume (30 Days)
- DSGN 141.5K
- WNEB 79.7K
- Earning Date
- DSGN 08-07-2025
- WNEB 07-22-2025
- Dividend Yield
- DSGN N/A
- WNEB 2.36%
- EPS Growth
- DSGN N/A
- WNEB N/A
- EPS
- DSGN N/A
- WNEB 0.59
- Revenue
- DSGN N/A
- WNEB $76,036,000.00
- Revenue This Year
- DSGN N/A
- WNEB N/A
- Revenue Next Year
- DSGN N/A
- WNEB $7.36
- P/E Ratio
- DSGN N/A
- WNEB $21.02
- Revenue Growth
- DSGN N/A
- WNEB 2.15
- 52 Week Low
- DSGN $2.60
- WNEB $7.63
- 52 Week High
- DSGN $7.77
- WNEB $12.41
- Technical
- Relative Strength Index (RSI)
- DSGN 61.90
- WNEB 73.86
- Support Level
- DSGN $4.68
- WNEB $11.63
- Resistance Level
- DSGN $5.60
- WNEB $11.95
- Average True Range (ATR)
- DSGN 0.39
- WNEB 0.28
- MACD
- DSGN 0.04
- WNEB 0.04
- Stochastic Oscillator
- DSGN 79.95
- WNEB 97.91
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.